Objective
Endometrial stromal sarcoma (ESS) is a rare form of uterine cancer, traditionally categorized as high-grade (HG) or low-grade (LG) ESS. Molecular and genomic changes that underlie the distinct clinical characteristics associated with each subtype are largely uncharacterized. We aim to identify genomic and protein expression differences between high-grade and low-grade tumors in a large cohort of ESS.